Related Experiment Videos
Adverse effects of lumbar myelography with amipaque and dimer-X
Abstract:
The adverse effects in a series of 50 lumbar myelographies with Amipaque were compared with those in a corresponding series, examined with Dimer-X. Side effects occurred in 58% of the cases examined with Amipaque and in 68% of the Dimer-X series. No seizures occurred in 58% of the cases examined with Amipaque and in 68% of the Dimer-X series. No seizures occurred in either series but slight fibrillations of fasciculations appeared in 2 Dimer-X patients. Hyperreflexia of the legs was recorded in 22% of the Amipaque and in 36% of the Dimer-X cases. Other adverse reactions to the media were mild to moderate. Some burst activity, but no definite paroxysmal abnormality was noted in EEG recordings in 2 Amipaque cases. The low epileptogenicity of Amipaque has ensured a wider safety margin of lumbar myelography.
Insights
Amipaque is a safer contrast agent for lumbar myelography than Dimer-X, with fewer adverse effects. This study found Amipaque had a wider safety margin, reducing risks associated with the diagnostic procedure.
Area of Science:
- Radiology
- Neurology
- Pharmacology
Background:
- Lumbar myelography is a crucial diagnostic procedure.
- Contrast agents are essential for myelography but can cause adverse effects.
- Comparing the safety profiles of different contrast agents is vital for patient care.
Purpose of the Study:
- To compare the adverse effects of Amipaque and Dimer-X in lumbar myelography.
- To evaluate the safety margin of Amipaque for this procedure.
Main Methods:
- A comparative study involving 50 lumbar myelographies using Amipaque and a control series with Dimer-X.
- Systematic recording and comparison of all adverse events, including neurological and physiological responses.
- Electroencephalogram (EEG) recordings were analyzed for abnormalities.
Main Results:
- Amipaque showed a lower incidence of side effects (58%) compared to Dimer-X (68%).
- Hyperreflexia was less frequent with Amipaque (22%) than Dimer-X (36%).
- No seizures were observed with either agent; Amipaque demonstrated lower epileptogenicity.
Conclusions:
- Amipaque offers a superior safety profile for lumbar myelography compared to Dimer-X.
- The reduced adverse effects and lower epileptogenicity of Amipaque contribute to a wider safety margin.
- Amipaque is recommended for lumbar myelography due to its enhanced safety characteristics.